The effect of topical steroid to prevent 5FU+ cisplatin induced phlebitis: a randomized, double-blind, placebo control, parallel group study.

The effect of topical steroid to prevent 5FU+ cisplatin induced phlebitis: a randomized, double-blind, placebo control, parallel group study. - The effect of topical steroid to prevent 5FU+ cisplatin induced phlebitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017262

Enrollment

Registered

2015-05-01

Start date

2015-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phlebitis from 5FU+ cisplatin therapy

Interventions

Twice a day (morning and evening) of topical steroid during FP therapy (4 or 5days). Twice a day (morning and evening) of placebo ointment (Vaseline) during FP therapy (4 or 5days).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all the following conditions (1)a candidate for FP therapy more than once (2)planed to be obtain peripheral vascular access for chemotherapy (3)Signed informed consent for this study

Exclusion criteria

Exclusion criteria: (1)Difficult to accept the researcher by mental disorder, cognitive impairment or physical disability (2)using topical steroid on upper arm(e.g.dermatitis treatments) (3)Inappropriate for this study in physician judgement

Design outcomes

Primary

Measure	Time frame
Length of the pigmentation of the first day of the second cycle of chemotherapy	—

Secondary

Measure	Time frame
Length of the induration Occurrence of the phlebitis The number of days of developing phlebitis	—

Countries

Japan

Contacts

Public ContactYoko Hamabe

Kyoto university hospital Nursing depertment

yhamabe@kuhp.kyoto-u.ac.jp075-366-7500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026